Legend: Boston Convention & Exhibition Center = CC, Westin Boston Waterfront = W, Seaport Boston Hotel = S
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 319 * | Tue, 8/5/2014, 10:30 AM - 12:20 PM | CC-156A | |
| Impact of Missing Data on Trial Success and Approval of Potentially Efficacious Therapies — Topic Contributed Papers | |||
| Biopharmaceutical Section | |||
| Organizer(s): Abdul J. Sankoh, Vertex Pharmaceuticals | |||
| Chair(s): Yanqiong Zhang, Vertex Pharmaceuticals | |||
| 10:35 AM | Mitigating Missing Data: A Proactive Approach for Minimizing Occurrence in Clinical Trials — Carol Robertson-Plouch, Eli Lilly and Company ; Sarah Witt, Eli Lilly and Company ; Tina Oakes, Eli Lilly and Company | ||
| 10:55 AM | Considerations for Prevention and Handling of Missing Data in Clinical Trials — Cynthia DeSouza, Vertex Pharmaceuticals ; Abdul J. Sankoh, Vertex Pharmaceuticals | ||
| 11:15 AM | A Taxonomy of Estimands for Regulatory Clinical Trials with Discontinuations — Thomas Permutt, FDA | ||
| 11:35 AM | Missing Data in Clinical Trials:Tryng to Select Reasonable Approaches and Sorting Out Their Effect on Analysis — Ralph D'Agostino Sr., Boston University | ||
| 11:55 AM | Discussant: Boguang Zhen, CBER/FDA | ||
| 12:15 PM | Floor Discussion | ||
2014 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Professional Development program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.